Keynote Speakers

Thursday, October 20, 2016

Beau Toskich, M.D.

Assistant Professor and Associate Fellowship Director of Vascular and Interventional Radiology
University of Florida College of Medicine

Topic: Angiosomal Ablation

Locoregional therapy for the treatment and palliation of both primary and metastatic liver malignancy has undergone exponential growth within the past decade as both therapeutic technologies and data continue to advance at an exciting pace.  The indication and utilization of transarterial radioembolization has expanded to include neoadjuvant and definitive applications within management algorithms.  Methodical interrogation of hepatic tumoral neovascularity and liver angiosomal manipulation has allowed for ablative radioembolization to generate early outcomes typically reserved for surgical resection but performed safely in the out-patient setting with negligible morbidity.


Friday October 21, 2016

Michael V. Knopp, M.D., PhD

Professor of Radiology and Novartis Chair of Imaging Research
Ohio State University

Topic: MR and PET imaging in Veterinary Oncology – Current Capabilities in Diagnosis and Therapy Response Assessment




Saturday, October 22, 2015

William H. McBride, PhD, DSc
Professor of Radiation Oncology
Assistant Vice-Chancellor for Research
University of California, Los Angeles (UCLA)

Topic: The Biology behind Radiotherapy for Cancer: Past, Present, and Future

Radiation therapy (RT) for cancer has been around for a long time and has evolved as a treatment along with the development of new technologies for radiation delivery. The biological basis for conventional delivery of radiation in 1.8-2.0Gy daily dose fractions 5 times per week at a moderate dose rate was derived empirically. However, it was given credence by elucidation of the 4Rs of radiobiology related to the possible advantages of dose fractionation. The recent advent of IMRT, IGRT, SRS, SRT, SBRT, Cyberknife, Gammaknife, Tomotherapy, RapidArc, HDR brachytherapy, protons, etc, has however encouraged or forced the use of smaller margins, inhomogeneous fields, adaptive radiotherapy, dose painting, and of larger dose fractions with considerable variation in delivery time and dose rate. The biological consequences of many of these changes are essentially unknown, but the way RT is being delivered is changing rapidly. At the same time, RT is seen as being much more than a cytotoxic agent. Of considerable interest is that it can act as an immunological adjuvant. As a result it is being explored in combination with various immunotherapies, in particular immune checkpoint inhibitors. This lecture will deal evaluate some of the constraints on the use of RT in the current era and will discuss where RT may be going in future efforts to improve radiotherapeutic benefit.


Mathieu Spriet, DVM, MS
Associate Professor of Diagnostic Imaging
University of California, Davis

Topic: PET of the Equine Distal Limb: Initial Experiences and Future Promise

Recent technological advancements have made Positron Emission Tomography (PET) available for imaging the equine distal limb. The first PET scan of a horse was performed at UC Davis in the spring of 2015 using a high resolution portable PET scanner. This newly available imaging technology provides access to cross-sectional functional imaging of the most commonly imaged anatomic region of the horse. Initial data suggests that PET will yield valuable additional information when compared with other imaging techniques, in particular for the determination of the activity of both soft tissue and osseous lesions. PET also appears to be more sensitive than other imaging modalities in detecting early or occult osseous lesions.